Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07397338 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors

StatusRecruiting
PhasePhase 1/2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Trial sites expanded: 6 → 9 locationsv7
  2. Site contacts updated at 1 of 6 sitesv6
  3. Study sites: 5 to 6v5
  4. Site contacts updated at 1 of 5 sitesv4
  5. Site contacts updated at 2 of 5 sitesv3
  6. Trial sites expanded: 1 → 5 locationsv2
  7. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of RAS(ON) inhibitors in combination with ivonescimab in adults with advanced or metastatic solid tumors with a RAS mutation.
Trial Details
NCT Number NCT07397338
Lead Sponsor Revolution Medicines, Inc.
Collaborators: Summit Therapeutics
Conditions Advanced Solid Tumors, Metastatic Solid Tumors, Non-small Cell Lung Cancer (NSCLC), NSCLC, Colorectal Cancer (CRC), CRC
Enrollment 370 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov